| 摘要 |
ABSTRACT - 599939 The disclosure relates to a therapeutic combination phosphatidylinositol 3-kinase (PI3-kinase or PI3K) inhibitor of formulae (I) or (II) and a mitogen activated protein kinase (MEK) inhibitor of formula (III) which is suitable for treating a patient with locally advanced or metastatic solid tumors, wherein the therapeutic combination is formulated for administration as a combined formulation or by alternation. Cancers such as melanoma, colorectal, pancreatic, ovarian, NSCLC, and thyroid cancers that have a high and overlapping frequency of oncogenic mutations that activate both RAS and PI3K pathways can be treated by said combined MEK and PI3K inhibition. |
